(Aurora, Ontario) – Helix BioPharma Corp. (hereinafter defined as “Helix” or the “Company” and listed on TSX & FSE: “HBP”), a biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, announces that Dr. Zbigniew Markowski will be stepping down, for personal and family reasons, from his positions as Chief Executive Officer of Helix BioPharma Corp and Chairman of Helix Polska, effective March 29th, 2016. Stepping into both roles, effective immediately, will be Dr. Sven Rohmann.
- 0 Comments
- FY2016